Genitourinary Cancer
From the Journals
One-month delay in cancer treatment linked to increase in mortality
The risk of death varied by treatment type.
From the Journals
Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC
The combination produced a survival benefit in the overall population but not among patients with favorable-risk disease.
From the Journals
No benefit with adjuvant sorafenib in intermediate-/high-risk RCC
Survival was similar with adjuvant sorafenib and placebo.
From the Journals
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
Conference Coverage
PET guidance for radiation therapy improves prostate cancer outcomes
Using PET as well as conventional imaging to guide postprostatectomy radiation therapy reduces the risk of treatment failure.
Conference Coverage
SRS instead of WBRT for patients with multiple brain metastases
Conference Coverage
Cancer therapy affects sexual health in most patients
Conference Coverage
Single and multifraction SBRT found comparable for lung metastases
A single-fraction regimen and a four-fraction regimen netted essentially the same toxicity and oncologic outcomes at 1 year of follow-up.
From the Journals
‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients
The NCI-MATCH trial has led to new clinical trial benchmarks, according to the study chair.
Conference Coverage
Lower BP and better tumor control with drug combo?
From the Journals
Novel assay may better detect urothelial carcinoma
The UroCAD assay proved more sensitive than urine cytology.